Claim
Strong Support
descriptive

Most teenage boys with fatty liver disease already have poor heart health markers, with only 1 in 10 having optimal levels and most falling in the middle range, suggesting this group is at elevated risk.

61
Pro
0
Against

Evidence from Studies

No evidence studies found yet.

What Would Prove This

Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.

1
Systematic Reviews & Meta-Analyses

The pooled prevalence of suboptimal cardiovascular health (LE8 score <80) in adolescents with MASLD across diverse populations and diagnostic criteria.

A systematic review and meta-analysis of all published studies reporting LE8 scores or equivalent CVH metrics in adolescents (11–18 years) with MASLD, stratified by diagnostic method (imaging, biomarkers), ethnicity, and BMI category, using standardized outcome definitions.

2
Cohort Studies

Whether adolescents with MASLD develop progressively worse CVH over time compared to peers without MASLD.

A prospective cohort of 500 adolescents aged 12–18, 250 with MASLD and 250 without, followed for 5 years with annual CVH assessments using Life’s Essential 8, adjusting for diet, activity, and socioeconomic status.

3
Cross-Sectional Studies

The prevalence of moderate or low CVH in adolescents with MASLD in a representative population sample.

A nationally representative cross-sectional survey of 1,000 adolescents aged 11–16 with MASLD (confirmed by imaging) and 1,000 without, measuring CVH using standardized LE8 metrics and demographic covariates.

4
Case Reports & Case Series

Individual examples of adolescents with MASLD and severely impaired CVH scores, illustrating clinical variability.

A case series of 20 adolescents with MASLD and LE8 scores below 50, documenting detailed clinical, dietary, and metabolic profiles to illustrate extreme phenotypes.

5
Expert Opinion & Narrative Reviews

Expert consensus on whether MASLD in adolescence is a marker of poor cardiovascular health.

A Delphi consensus process involving 30 pediatric hepatologists and cardiologists to rate the strength of association between MASLD and CVH impairment, based on clinical experience and literature.

Sign up to see full verdict